Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

• ClinicalTrials.gov Identifier: NCT02897375
• Recruitment Status: Recruiting
• First Posted: September 13, 2016
• Last Update Posted: February 20, 2020
• Sponsor: Emory University
• Collaborator: Pfizer
• Information provided by (Responsible Party): Taofeek K. Owonikoko, Emory University

Study Description

Brief Summary:

This phase I trial studies the side effects and best dose of palbociclib with cisplatin or carboplatin in treating patients with solid tumors that have spread to other places and usually cannot be cured or controlled with treatment. Palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving palbociclib with cisplatin or carboplatin may help stop tumor growth in patients with advanced solid tumors.

Condition or disease	Intervention/treatment	Phase
Solid Neoplasm; Stage III Pancreatic Cancer; Stage IIIA Breast Cancer; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Breast Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Stage IV Non-Small Cell Lung Cancer; Stage IVA Pancreatic Cancer; Stage IVB Pancreatic Cancer; Sarcoma; Colorectal Cancer; Head and Neck Cancer; Cancer of Unknown Primary; Bladder Cancer; Ovarian Cancer	Drug: Carboplatin; Drug: Cisplatin; Drug: Palbociclib	Phase 1

Detailed Description:

PRIMARY OBJECTIVES:

I. Assess the safety and tolerability of palbociclib when administered along with cisplatin or carboplatin.

II. Establish the recommended phase 2 dose (RP2D) of the tested combinations.

SECONDARY OBJECTIVES:

I. Characterize the pharmacokinetic (PK) profiles of cisplatin, carboplatin.

II. Obtain preliminary evidence of anti-tumor efficacy of the tested combination regimens.

III. Conduct PK/pharmacodynamics (PD) correlative analyses using palbociclib trough concentration and cyclin-dependent kinase 4 (CDK4) inhibition read-outs in tumor and surrogate samples collected on course 1 day 22 (C1D22).

IV. Assess potential association between tissue-based biomarkers and efficacy.

OUTLINE: This is a dose-escalation study. Patients are assigned to 1 of 2 arms.

ARM A: Patients receive cisplatin intravenously (IV) over 30-60 minutes on day 1 and palbociclib orally (PO) once daily (QD) on days 2-22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

ARM B: Patients receive carboplatin IV over 30-60 minutes on day 1 and palbociclib PO QD on days 2-22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed for up to 4 weeks.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 90 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 1 Study of Palbociclib in Combination With Cisplatin or Carboplatin in Advanced Solid Malignancies
• Study Start Date: October 2016
• Estimated Primary Completion Date: December 2020
• Estimated Study Completion Date: December 2021

Arms and Interventions

Arm	Intervention/treatment
Experimental: Arm A (palbociclib, cisplatin); Patients receive cisplatin IV over 30-60 minutes on day 1 and palbociclib PO QD on days 2-22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.	Drug: Cisplatin; Given IV; Other Names: CDDP; Cis-diamminedichloridoplatinum; Cisplatinum; Cismaplat; Neoplatin; Drug: Palbociclib; Given PO; Other Names: Ibrance; PD-0332991
Experimental: Arm B (palbociclib, carboplatin); Patients receive carboplatin IV over 30-60 minutes on day 1 and palbociclib PO QD on days 2-22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.	Drug: Carboplatin; Given IV; Other Name: Paraplatin; Drug: Palbociclib; Given PO; Other Names: Ibrance; PD-0332991

Outcome Measures

Primary Outcome Measures :

1. Incidence of adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 [ Time Frame: Study completion, an average of 2 years ]
2. Incidence of dose limiting toxicities defined as grade 3 or higher toxicity [ Time Frame: Up to 4 weeks ]
3. Recommended phase 2 dose (RP2D) as the highest doses of palbociclib and cisplatin or palbociclib and carboplatin [ Time Frame: Study completion, an average of 2 years ]

Secondary Outcome Measures :

1. Overall response rate (complete response + partial response) assessed by Response Evaluation Criteria in Solid Tumors 1.1 criteria [ Time Frame: Up to 3 years ]
   Will be summarized and presented along with 95% exact confidence intervals.
2. Pharmacokinetic (PK) characteristics of carboplatin including maximum concentration (Cmax) [ Time Frame: Up to 4 weeks ]
   Within-subject and between-cohort comparisons of Cmax will be performed using Wilcoxon (non-parametric) test.
3. Pharmacokinetic (PK) characteristics of cisplatin including maximum concentration (Cmax) [ Time Frame: Up to 4 weeks ]
   Within-subject and between-cohort comparisons of Cmax will be performed using Wilcoxon (non-parametric) test.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Patients must have histologically or cytologically confirmed solid organ malignancy
• Patients enrolled in the expansion cohort must have histologically or cytologically confirmed squamous non-small cell lung cancer (NSCLC), breast or pancreaticobiliary tract cancer
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
• Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥ 20 mm (≥ 2 cm) with conventional techniques or as ≥ 10 mm (≥ 1 cm) with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam
• Leukocytes ≥ 3,000/mL
• Absolute neutrophil count ≥ 1,500/mL
• Platelets ≥ 100,000/mL
• Hemoglobin ≥ 10 g/dL
• Total bilirubin ≤ 1.5 × institutional upper limit of normal (except for patients with Gilbert disease)
• Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/ alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) ≤ 2.5 × institutional upper limit of normal (up to 5 X upper limit of normal [ULN] for patients with liver metastasis)
• Creatinine within normal institutional limits OR creatinine clearance ≥ 60 mL/min/1.73 m² for patients with creatinine levels above institutional normal
• Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for 6 months after completion of study drug administration
• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

• Patients who have had cytotoxic anticancer chemotherapy or immune checkpoint inhibitor within 4 weeks (6 weeks for nitrosoureas or mitomycin C) or palliative radiation within 2 weeks (stereotactic radiation therapy [SRS] for brain metastasis within 48 hours) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
• Patients receiving cytotoxic agent as immunomodulatory therapy for a non neoplastic indication (e.g. methotrexate for rheumatoid arthritis) and who are unable to discontinue such agents within 2 weeks prior to starting treatment
• Oral targeted therapy within five days or five half-lives, whichever is longer, prior to initiating protocol therapy treatment
• Patients who are receiving any other investigational agents
• Use of strong cytochrome P450, family 3, subfamily A (CYP3A) inhibitors and inducers
• Patients with symptomatic uncontrolled brain metastases are excluded; (patients with stable treated or asymptomatic untreated brain metastasis not requiring glucocorticoids are allowed)
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib, carboplatin or cisplatin
• Concurrent administration of strong inducers and inhibitors of CYP3A enzyme or CYP3A substrates with narrow therapeutic window

• Uncontrolled intercurrent illness including, but not limited to:

  • Ongoing or active infection requiring intravenous antibiotics at the time of treatment initiation
  • Symptomatic congestive heart failure (requiring hospital stay within the last 6 months)
  • Myocardial infarction within the last 6 months
  • Unstable angina pectoris, cardiac arrhythmia
  • Psychiatric illness
• Social situations or circumstances that would limit compliance with study requirements
• Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with palbociclib
• Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Contacts and Locations

Contacts

Contact: Taofeek Owonikoko, MD, PhD; 404-778-4383; towonik@emory.edu

Contact: Suresh Ramalingam, MD; 404-778-4383; ssramal@emory.edu

Locations

United States, Georgia

Emory University/Winship Cancer Institute; Recruiting

Atlanta, Georgia, United States, 30322

Contact: Nakita Brown 404-616-9850 nlbrown@emory.edu

Contact: Monique Williams 404-778-4383 monique.guyinn@emory.edu

Sponsors and Collaborators

Emory University

Pfizer

Investigators

• Principal Investigator: Taofeek Owonikoko, MD, PhD; Emory University

More Information

• Responsible Party: Taofeek K. Owonikoko, Principal Investigator, Emory University
• ClinicalTrials.gov Identifier: NCT02897375
• Other Study ID Numbers: IRB00089583; NCI-2016-01037 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ); Winship3263-16 ( Other Identifier: Emory University/Winship Cancer Institute )
• First Posted: September 13, 2016
• Last Update Posted: February 20, 2020
• Last Verified: February 2020

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

Additional relevant MeSH terms:

Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Pancreatic Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Respiratory Tract Neoplasms; Thoracic Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Endocrine Gland Neoplasms; Pancreatic Diseases; Endocrine System Diseases; Cisplatin; Carboplatin; Palbociclib; Antineoplastic Agents; Protein Kinase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action